Michael Barbella07.08.21
The first patients in the United States have been treated with Rapid Medical’s U.S. Food and Drug Administration (FDA)-cleared TIGERTRIEVER revascularization device by Dr. Rishi Gutpa, director of Neurocritcal Care at Wellstar Health System in Georgia. TIGERTRIEVER is the first adjustable stent retriever, enabling neuro interventionalists to better remove blood clots and restore blood flow to the brain following an ischemic event—a condition that devastates 800,000 Americans annually.
“With TIGERTRIEVER, I can adjust the sizing of the device to more safely engage and retrieve the blood clot,” says Dr. Gupta. “Additionally, the TIGERTRIEVER 17 device has the smallest diameter of any clot retriever, allowing me to treat occlusions further in the brian. This new class of mechanical thrombectomy devices shows significant clinical potential for the treatment of stroke.”
TIGERTRIEVER provides physicians with greater intraoperative control. Physicians adjust the device according to procedural intelligence, individualizing the approach for each patient. The recently published TIGER Trial, completed for FDA clearance, demonstrated the benefits of this technique.
The trial documented TIGERTRIEVER’s superiority over conventional stent retrievers, achieving a statistically significant improvement in the ability to restore blood flow to the brain and excellent comparable safety metrics. Even in the smaller, more difficult to treat brain vessels, TIGERTRIEVER 17 achieved 92 percent revascularization success.
“Unlike devices currently available to treat ischemic stroke, the TIGERTRIEVER’s unique design allows the physician enhanced control in sizing the stent to the specific patient blood vessel increasing the likelihood of full restoration of blood flow,” says James Romero, President, Americas, Rapid Medical. “Today marks a significant milestone in the advancement of stroke treatment. We are excited to bring innovative solutions to the market to help improve patient outcomes.”
TIGERTRIEVER is available in the United States in two sizes, 21 and 17, applicable for a wide range of large vessel occlusions.
Rapid Medical develops the premier responsive interventional devices for neurovascular diseases such as ischemic and hemorrhagic stroke. Utilizing novel manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the intravascular environment and have greater control over procedural outcomes. TIGERTRIEVER, COMANECI and COLUMBUS/DRIVEWIRE are CE marked and FDA cleared.
“With TIGERTRIEVER, I can adjust the sizing of the device to more safely engage and retrieve the blood clot,” says Dr. Gupta. “Additionally, the TIGERTRIEVER 17 device has the smallest diameter of any clot retriever, allowing me to treat occlusions further in the brian. This new class of mechanical thrombectomy devices shows significant clinical potential for the treatment of stroke.”
TIGERTRIEVER provides physicians with greater intraoperative control. Physicians adjust the device according to procedural intelligence, individualizing the approach for each patient. The recently published TIGER Trial, completed for FDA clearance, demonstrated the benefits of this technique.
The trial documented TIGERTRIEVER’s superiority over conventional stent retrievers, achieving a statistically significant improvement in the ability to restore blood flow to the brain and excellent comparable safety metrics. Even in the smaller, more difficult to treat brain vessels, TIGERTRIEVER 17 achieved 92 percent revascularization success.
“Unlike devices currently available to treat ischemic stroke, the TIGERTRIEVER’s unique design allows the physician enhanced control in sizing the stent to the specific patient blood vessel increasing the likelihood of full restoration of blood flow,” says James Romero, President, Americas, Rapid Medical. “Today marks a significant milestone in the advancement of stroke treatment. We are excited to bring innovative solutions to the market to help improve patient outcomes.”
TIGERTRIEVER is available in the United States in two sizes, 21 and 17, applicable for a wide range of large vessel occlusions.
Rapid Medical develops the premier responsive interventional devices for neurovascular diseases such as ischemic and hemorrhagic stroke. Utilizing novel manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real-time to the intravascular environment and have greater control over procedural outcomes. TIGERTRIEVER, COMANECI and COLUMBUS/DRIVEWIRE are CE marked and FDA cleared.
